drugset / Trial / NCT05398393

An Experimental Study on the Effect of Tenofovir Amibufenamide on Blood Lipid During Anti-HBV Treatment

NCT05398393

Non-randomizedSingle-groupOpen-labelTreatment

Summary

In June 2021, Chinese Food and Drug Administration approved the launch of the self-developed new drug Tenofovir Amibufenamide(TMF). TMF is a new second generation of tenofovir(TFV) and its effect on blood lipids is unclear. Our study aims to figure out the effect of TMF on serum lipid level in the process of antiviral therapy for chronic hepatitis B patients.

Timeline

Start
2022-01-01
Primary completion
2023-06-30
Completion
2023-06-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenofovir Amibufenamide Unknown 25 mg Oral
Background Amlodipine Other / unclassified
Background Atorvastatin Small molecule